Abstract
Carfilzomib is a proteasome inhibitor that is approved for use as a single agent in patients with relapsed and refractory multiple myeloma and when used in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma (1-3 prior lines of therapy). Cardiac and cardiopulmonary adverse events have been reported to be associated with carfilzomib-based treatment regimens. This article discusses the cardiac-related adverse events that have been reported in clinical studies of carfilzomib and presents a single institution perspective on the prevention and management of cardiac adverse events following treatment with this agent.
Original language | English (US) |
---|---|
Pages (from-to) | 241-245 |
Number of pages | 5 |
Journal | Clinical Lymphoma, Myeloma and Leukemia |
Volume | 16 |
Issue number | 5 |
DOIs |
|
State | Published - May 1 2016 |
Keywords
- Cardiopulmonary
- Clinical trials
- Multiple myeloma
- Proteasome inhibitor
- Review
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research